Key Points
- Insider sale: On Jan. 12 Sukumar Nagendran sold 200,000 Taysha (TSHA) shares at an average of $4.71 for $942,000, leaving him with 1,006,439 shares — a 16.58% cut in his ownership.
- That sale is part of a recent pattern: Nagendran sold 110,125 shares on Nov. 28 and 260,047 on Dec. 1, totaling 570,172 shares sold for roughly $2.64 million over the past months.
- TSHA trades near $5 with a $1.38 billion market cap and negative earnings/margins, yet analysts hold a mixed view with a consensus rating of "Moderate Buy" and a consensus target of $10.67 (some bullish upgrades and some sell ratings).
Taysha Gene Therapies, Inc. (NASDAQ:TSHA - Get Free Report) insider Sukumar Nagendran sold 200,000 shares of the firm's stock in a transaction dated Monday, January 12th. The shares were sold at an average price of $4.71, for a total value of $942,000.00. Following the sale, the insider owned 1,006,439 shares in the company, valued at $4,740,327.69. This trade represents a 16.58% decrease in their ownership of the stock. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available at this link.
Sukumar Nagendran also recently made the following trade(s):
- On Friday, November 28th, Sukumar Nagendran sold 110,125 shares of Taysha Gene Therapies stock. The stock was sold at an average price of $4.75, for a total value of $523,093.75.
- On Monday, December 1st, Sukumar Nagendran sold 260,047 shares of Taysha Gene Therapies stock. The stock was sold at an average price of $4.51, for a total transaction of $1,172,811.97.
Taysha Gene Therapies Stock Up 2.9%
TSHA stock opened at $5.04 on Thursday. Taysha Gene Therapies, Inc. has a 52 week low of $1.05 and a 52 week high of $6.02. The firm has a 50-day simple moving average of $4.97 and a 200-day simple moving average of $3.93. The company has a quick ratio of 10.48, a current ratio of 10.48 and a debt-to-equity ratio of 0.23. The stock has a market capitalization of $1.38 billion, a P/E ratio of -15.27 and a beta of 1.02.
Taysha Gene Therapies (NASDAQ:TSHA - Get Free Report) last released its earnings results on Tuesday, November 4th. The company reported ($0.09) earnings per share for the quarter, meeting the consensus estimate of ($0.09). Taysha Gene Therapies had a negative return on equity of 67.26% and a negative net margin of 1,144.97%. Equities analysts forecast that Taysha Gene Therapies, Inc. will post -0.35 earnings per share for the current fiscal year.
Wall Street Analysts Forecast Growth
A number of analysts have issued reports on TSHA shares. Wells Fargo & Company raised their target price on Taysha Gene Therapies from $8.00 to $11.00 and gave the stock an "overweight" rating in a research note on Monday, January 5th. Citigroup restated an "outperform" rating on shares of Taysha Gene Therapies in a research note on Wednesday, November 5th. Raymond James Financial restated a "strong-buy" rating and issued a $13.00 price objective on shares of Taysha Gene Therapies in a report on Tuesday, January 6th. Weiss Ratings reissued a "sell (d-)" rating on shares of Taysha Gene Therapies in a research note on Monday, December 29th. Finally, Wall Street Zen lowered shares of Taysha Gene Therapies from a "hold" rating to a "sell" rating in a report on Saturday, January 3rd. One equities research analyst has rated the stock with a Strong Buy rating, eleven have assigned a Buy rating and one has given a Sell rating to the stock. According to MarketBeat, the company currently has an average rating of "Moderate Buy" and a consensus target price of $10.67.
Check Out Our Latest Analysis on Taysha Gene Therapies
Hedge Funds Weigh In On Taysha Gene Therapies
Hedge funds have recently made changes to their positions in the company. Jefferies Financial Group Inc. increased its position in shares of Taysha Gene Therapies by 4,105.3% during the second quarter. Jefferies Financial Group Inc. now owns 10,313,733 shares of the company's stock worth $23,825,000 after purchasing an additional 10,068,479 shares in the last quarter. Adage Capital Partners GP L.L.C. purchased a new position in Taysha Gene Therapies during the 2nd quarter worth approximately $11,178,000. Barclays PLC increased its position in Taysha Gene Therapies by 1,042.8% during the third quarter. Barclays PLC now owns 5,148,112 shares of the company's stock worth $16,834,000 after buying an additional 4,697,611 shares during the period. MPM Bioimpact LLC purchased a new stake in Taysha Gene Therapies in the second quarter valued at approximately $6,823,000. Finally, Vestal Point Capital LP lifted its stake in Taysha Gene Therapies by 83.3% in the third quarter. Vestal Point Capital LP now owns 5,500,000 shares of the company's stock valued at $17,985,000 after buying an additional 2,500,000 shares during the last quarter. Hedge funds and other institutional investors own 77.70% of the company's stock.
About Taysha Gene Therapies
(
Get Free Report)
Taysha Gene Therapies, Inc (NASDAQ: TSHA) is a clinical-stage biotechnology company focused on developing gene therapies for rare monogenic diseases of the central nervous system. Using a proprietary adeno-associated viral (AAV) vector platform, the company engineers novel capsids and regulatory elements to optimize delivery and expression of therapeutic genes. Its pipeline features lead programs such as TSHA-102 for GM2 gangliosidoses (Tay–Sachs and Sandhoff diseases), TSHA-101 for GM1 gangliosidosis and TSHA-103 for aromatic l-amino acid decarboxylase (AADC) deficiency, alongside earlier-stage candidates targeting other life-threatening pediatric CNS disorders.
Founded in 2019 and headquartered in Dallas, Texas, Taysha Gene Therapies completed its initial public offering in May 2021.
Featured Articles
This instant news alert was generated by narrative science technology and financial data from InsiderTrades.com in order to provide readers with the fastest and most accurate reporting. Please send any questions or comments about this story to [email protected].
